Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
    • Recent News
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Events
  • Recent News

DelMar Pharmaceuticals Receives Nasdaq Listing Extension

Feb 7, 2019

DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

Nov 20, 2018

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results

Nov 14, 2018

DelMar Announces Further Validation of the Mechanism of Action of VAL-083

Oct 10, 2018

DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results

Sep 24, 2018

DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor

Sep 4, 2018

DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM

Jun 26, 2018

DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors

Jun 25, 2018

DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

May 22, 2018

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results

May 17, 2018
    • 1...
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • ...32
    © 2022 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences